• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [20337 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2016     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Acute neck and back pain: preventive interventions – Effects of physical training, manual treatment and cognitive behavioral interventions]
2013     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Acute pain treatment on postoperative and medical non-surgical wards]
2006     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Adalimumab for treating rheumatoid arthritis]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Adalimumab, etanercept, infliximab and golimumab for the treatment of ankylosing spondylitis and reactive arthritis]
2009     Committee for New Health Technology Assessment (CNHTA) [ADAMTS 13 Activity]
2013     Basque Office for Health Technology Assessment (OSTEBA) [Adaptation and assessment of an online research methodology training course for nurses]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Adaptation to the Catalan health care system of the clinical practice guideline 'Management of major depression in adults']
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A12-15 Crizotinib]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A12-16 Saxagliptin/metformin]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A12-18 (dapagliflozin)]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A13-03 (sitagliptin/metformin)]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A13-05 (fidaxomicin)]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A13-06 (Abiraterone acetate [New therapeutic indication])]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A13-09 (vandetanib)]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A13-10 (pertuzumab)]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A13-16 (vildagliptin)]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A13-17 (vildagliptin/metformin)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A13-33 (enzalutamide)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A13-35 (dabrafenib)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A13-37 (regorafenib)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A13-44 (ipilimumab, new therapeutic indication)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A14-05 (sofosbuvir)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A14-12 (canagliflozin)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A14-14 (dimethyl fumarate)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A14-18 (simeprevir)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A14-19 (mirabegron)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A14-21 (Fingolimod)]
2015     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A14-22 (Umeclidinium/vilanterol)]
2015     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A14-26 (empagliflozin)]
2015     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A14-28 (apixaban)]
2015     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A14-31 (daclatasvir)]
2011     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to the final report A09-02 (benefit assessment of prasugrel)]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Addendum to the notice on the efficacy of rehabilitative interventions and pharmacological therapies for children aged 2 to 12 Years with autism spectrum disorder (ASD)]
2008     Committee for New Health Technology Assessment (CNHTA) [Adenovirus, nested PCR]
2006     The Netherlands Organisation for Health Research and Development (ZonMw) [Adherence to guidelines in ambulatory patients with mild heart failure and associated organisational factors]
2016     National Evidence-based Healthcare Collaborating Agency (NECA) [Advantages of vestibular rehabilitation on the vestibular neuritis]
2013     Institut national d'excellence en sante et en services sociaux (INESSS) [Advisability of expanding the Québec newborn blood screening program]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Afamelanotide - Assessment according to §35a (para. 1., sentence 10) Social Code Book V]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Afamelanotide (erythropoietic protoporphyria) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Afatinib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2015     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Afatinib - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Afatinib (new therapeutic indication) - benefit assessment according to §35a Social Code Book V]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aflibercept - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2015     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aflibercept (Addendum to Commission A14-32)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aflibercept (extension of approval) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aflibercept (Eylea) extension of approval - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2015     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aflibercept (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aflibercept (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aflibercept (Zaltrap) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Aflibercept for age-related macular degeneration and central retinal vein occlusion]
2009     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Age-related macular degeneration: the role of current treatment strategies]
2008     Committee for New Health Technology Assessment (CNHTA) [AGL gene, mutation[sequencing]]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Albiglutide - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2011     Haute Autorite de sante (HAS) [Albumin (or protein) to creatinine ratios in the diagnosis of chronic kidney disease in adults]
2009     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Albumin Dialysis and Molecular Adsorbent Recirculating System (MARS) in the treatment of liver failure]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Albutrepenonacog alfa - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Albutrepenonacog alfa (haemophilia B) - Assessment according to §35a Social Code Book V]
2018     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alectinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alectinib (non-small-cell lung cancer) - Addendum to commission A17-19]
2018     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alectinib (non-small-cell lung cancer) - Addendum to Commission A17-67]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alectinib (NSCLC) - Benefit assessment according to §35a Social Code Book V]
2003     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Alefacept (Amevive(R)) for the treatment of severe psoriasis]
2016     Institute for Clinical Effectiveness and Health Policy (IECS) [Alemtuzumab for multiple sclerosis]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Alemtuzumab in multiple sclerosis]
2014     Andalusian Health Technology Assessment Area (AETSA) [Alglucosidase alfa (Myozyme ®) in late-onset Pompe disease]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Alglucosidase alpha (Myozyme) for treatment of patients with late-onset Pompe disease]
2015     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alipogene tiparvovec - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alirocumab - Addendum to Commission A15-47]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alirocumab - Benefit assessment according to §35a Social Code Book V]
2019     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alirocumab (primary hypercholesterolaemia or mixed dyslipidaemia) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Alirocumab for patients with hypercholesterolemia]
2012     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aliskiren / Amlodipine (combination of active ingredients) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
1999     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Allergic diseases: suggestions concerning organization of prevention, diagnostics and treatment (funded by DIHTA)]
2009     Committee for New Health Technology Assessment (CNHTA) [Allo skin graft]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Allocation of scarce resources in critical care units in a pandemic]
2019     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Allogeneic stem cell transplantation in aggressive B-cell non-Hodgkin lymphoma and in T-cell non-Hodgkin lymphoma]
2018     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Allogeneic T cells (high-risk haematological malignancies) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2012     Andalusian Health Technology Assessment Area (AETSA) [Allomap genetic test for cardiac transplant rejection]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alpelisib (breast cancer) - Addendum to Commission A20-81]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alpelisib (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2008     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Alpha1 antitrypsin]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Alprostadil for nonrevascularizable critical lower limb ischemia]
2012     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Alternative methods for the treatment of post-menopausal troubles]
2015     Haute Autorite de sante (HAS) [Alternative(s) to 99mTc-sestamibi preoperative scintigraphy for the localization of hypersecreting parathyroid glands in the event of complete shortage of 99mTechnetium (99mTc)]
2015     Norwegian Institute of Public Health (NIPH) [Alternatives of plasma for transfusion to patients]
2001     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Alternatives to blood transfusion]
2013     Basque Office for Health Technology Assessment (OSTEBA) [Alternatives to short stay psychiatric hospitalisation. Intensive ambulatory monitoring programmes]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Ambrisentan (Volibris) in the treatment of pulmonary arterial hypertension]
2009     Committee for New Health Technology Assessment (CNHTA) [Ambulatory esophageal multichannel impedence pH monitoring]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Ambulatory oxygen therapy in COVID-19]
1998     Basque Office for Health Technology Assessment (OSTEBA) [Ambulatory ultrasound in Basque country: current status, recommendations on its use and practice]
2009     Committee for New Health Technology Assessment (CNHTA) [AMH]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Amifampridine (Firdapse) for the treatment of Lambert Eaton Myasthenic Syndrome]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Amikacin sulfate (Mycobacterium avium Complex [MAC] lung infections) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Amivantamab (NSCLC) - Benefit assessment according to §35a Social Code Book V]
2009     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Amotosalen (Intercept) for the inactivation of pathogens for transfusion therapy]
2007     Andalusian Health Technology Assessment Area (AETSA) [AmpliChip CYP450: Cytochrome P450 genotyping in psychiatric patients]
2018     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Amyloid PET in dementia of unclear aetiology (Addendum to Commission E18-03)]
2018     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Amyloid PET in dementia of unclear aetiology]
2014     Basque Office for Health Technology Assessment (OSTEBA) [An evaluation of intensity-modulated radiotherapy (IMRT)]